FRESENIUS SE+CO.KGAA O.N./ DE0005785604 /
1/23/2025 5:25:21 PM | Chg. +0.890 | Volume | Bid9:14:14 PM | Ask9:14:14 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
36.800EUR | +2.48% | 18 Turnover: 661.860 |
36.850Bid Size: 500 | 36.890Ask Size: 500 | 20.71 bill.EUR | - | - |
GlobeNewswire
4/24/2024
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for ...
GlobeNewswire
4/23/2024
Transferring Biomedical Research to Patients Faster: ForTra gGmbH Announces Positive Funding Track R...
GlobeNewswire
2/23/2024
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatm...
GlobeNewswire
9/4/2023
CIO Leadership: Generative AI and Visionary Leadership in the Enterprise Will Power the Discussion a...
GlobeNewswire
8/31/2023
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil